Patents by Inventor George Stamatoyannopoulos

George Stamatoyannopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066148
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Application
    Filed: January 26, 2023
    Publication date: February 29, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Patent number: 11788101
    Abstract: Provided herein are methods for identifying high potency genomic insulator elements that can be used in a vector composition e.g., that are useful for preventing unwanted expression of neighboring genes, such as proto-oncogenes, when administered to a subject in need thereof. Also provided herein are methods for treating disease and methods for administering a nucleic acid to a subject using such vectors.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: October 17, 2023
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: George Stamatoyannopoulos, John Stamatoyannopoulos
  • Patent number: 11717579
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: August 8, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Publication number: 20200263202
    Abstract: Provided herein are methods for identifying high potency genomic insulator elements that can be used in a vector composition e.g., that are useful for preventing unwanted expression of neighboring genes, such as proto-oncogenes, when administered to a subject in need thereof. Also provided herein are methods for treating disease and methods for administering a nucleic acid to a subject using such vectors.
    Type: Application
    Filed: January 31, 2020
    Publication date: August 20, 2020
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: George Stamatoyannopoulos, John Stamatoyannopoulos
  • Patent number: 10590433
    Abstract: Provided herein are methods for identifying high potency genomic insulator elements that can be used in a vector composition e.g., that are useful for preventing unwanted expression of neighboring genes, such as proto-oncogenes, when administered to a subject in need thereof. Also provided herein are methods for treating disease and methods for administering a nucleic acid to a subject using such vectors.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: March 17, 2020
    Assignee: University of Washington
    Inventors: George Stamatoyannopoulos, John Stamatoyannopoulos
  • Publication number: 20170175136
    Abstract: Provided herein are methods for identifying high potency genomic insulator elements that can be used in a vector composition e.g., that are useful for preventing unwanted expression of neighboring genes, such as proto-oncogenes, when administered to a subject in need thereof. Also provided herein are methods for treating disease and methods for administering a nucleic acid to a subject using such vectors.
    Type: Application
    Filed: March 13, 2015
    Publication date: June 22, 2017
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: George Stamatoyannopoulos, John Stamatoyannopoulos
  • Publication number: 20170173185
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Michel Sadelain, Isabelle Riviere, Jorge Mansilla-Soto, Xiuyan Wang, George Stamatoyannopoulos, John Stamatoyannopoulos, Mingdong Liu
  • Publication number: 20100280113
    Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.
    Type: Application
    Filed: July 14, 2010
    Publication date: November 4, 2010
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
  • Publication number: 20080027136
    Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.
    Type: Application
    Filed: July 11, 2007
    Publication date: January 31, 2008
    Inventors: Douglas Faller, Susan Perrine, George Stamatoyannopoulos
  • Patent number: 7265153
    Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: September 4, 2007
    Inventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
  • Patent number: 7094398
    Abstract: The present invention provides for novel chimeric Ad-vectors carrying transgene, or portions of transgenes for stable and efficient gene transfer into diverse cell types or tissues in a CAR- and/or ???3/5-independent manner. Also provided are methods for producing such vectors and the use thereof for gene therapy to target a specific cell type or tissue.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: August 22, 2006
    Assignee: University of Washington
    Inventors: André Lieber, Dmitry M Shayakhmetov, Denise R Farrer, Thalia Papayannopoulou, George Stamatoyannopoulos
  • Publication number: 20030018069
    Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.
    Type: Application
    Filed: July 1, 2002
    Publication date: January 23, 2003
    Inventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
  • Publication number: 20010034367
    Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.
    Type: Application
    Filed: February 15, 2001
    Publication date: October 25, 2001
    Inventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
  • Patent number: 6184343
    Abstract: The invention is directed to fetal globin inducing factor (FGIF), and to nucleic acids encoding FGIF. FGIF controls the expression of fetal globin gene products. An FGIF polypeptide is shown in FIG. 3 and nucleotide sequences that encode FGIF polypeptides are shown in FIGS. 1 and 2. The invention is also directed to therapeutic methods employing FGIF polypeptides, encoding nucleic acids and functional fragments thereof for the treatment of globin disorders and to methods for screening compounds that modulate fetal globin gene expression as well as compounds identified by these methods.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: February 6, 2001
    Inventors: George Stamatoyannopoulos, Thalia Papayannopoulou
  • Patent number: 4965251
    Abstract: A method of treating a hemoglobinopathic condition such as sickle cell anemia, by pulse treatment with erythropoietin. In one embodiment, each of one or more treatment regimens includes a first time period during which erythropoietin is administered to a hemoglobinopathic patient and a second time period during which erythropoietin is withheld from the patient. During the first time period, sufficient erythropoietin is administered to increase F-reticulocyte formation in the patient. The pulse treatment preferably includes a plurality of the treatment regimens, in which case the durations of the second time periods are selected to achieve a cumulative increment of F-cell count sufficient to effectively treat the patient'This invention was made partly with government support under one or more of grants HL20899 and HL21676 from the National Institutes of Health. The government has certain rights in this invention.
    Type: Grant
    Filed: April 3, 1987
    Date of Patent: October 23, 1990
    Assignee: The Board of Regents of The University of Washington
    Inventor: George Stamatoyannopoulos